Abstract:In vitro autoradiography on tissue sections and receptor assay in cortical membrane homogenates revealed that pirenuzepine h-affinity muscarink sites (Ml) decrease in affinity in the prefrontal cortex and in other cortical areas of aged rhesus monkey (Macaca miudta). Carbachol competition experiments detected only a single, low-affinity da of sites in old monkeys, while two classes of sites (low and hh affity) were observed in young adults. The change in affinity in the aged monkeys is not accomaed by a decrea… Show more
“…For example, one study reported a modest reduction in ChAT levels in the frontal pole of aged rhesus monkeys (Wenk et al, 1989), but a subsequent study reported that the levels of this synthetic enzyme were not changed in the frontal cortex in a different cohort of aged monkeys (Wenk et al, 1991). Further, another study reported that neither M1 nor nicotinic ACh receptors are reduced with age in monkey prefrontal cortex (Wenk et al, 1989) while a subsequent study reported a significant decrease in M1 receptor binding in area 46 (Vannucchi and Goldman-Rakic, 1991). Clearly further work is required to unequivocally demonstrate whether cholinergic systems are substantially changed with age in the primate area 46.…”
Section: Neurotransmitter-specific Projections To Area 46 and Age-mentioning
This review is concerned with the effects of normal aging on the structure and function of prefrontal area 46 in the rhesus monkey (Macaca mulatta). Area 46 has complex connections with somatosensory, visual, visuomotor, motor and limbic systems and a key role in cognition, which frequently declines with age. An important question is what alterations might account for this decline. We are nowhere near having a complete answer, but as will be shown in this review, it is now evident that there is no single underlying cause. There is no significant loss of cortical neurons and although there are a few senile plaques in rhesus monkey cortex, their frequency does not correlate with cognitive decline. However, as discussed in this review, the following do correlate with cognitive decline. Loss of white matter, that has been proposed to result in some disconnections between parts of the central nervous system, and changes in the structure of myelin sheaths, that reduce conduction velocity and the timing in neuronal circuits. In addition, there are reductions in the inputs to cortical neurons, as shown by regression of dendritic trees, loss of dendritic spines and synapses, and alterations in transmitters and receptors. These factors contribute to alterations in the intrinsic and network physiological properties of cortical neurons. As more details emerge it is to be hoped that effective interventions to retard cognitive decline can be proposed.
“…For example, one study reported a modest reduction in ChAT levels in the frontal pole of aged rhesus monkeys (Wenk et al, 1989), but a subsequent study reported that the levels of this synthetic enzyme were not changed in the frontal cortex in a different cohort of aged monkeys (Wenk et al, 1991). Further, another study reported that neither M1 nor nicotinic ACh receptors are reduced with age in monkey prefrontal cortex (Wenk et al, 1989) while a subsequent study reported a significant decrease in M1 receptor binding in area 46 (Vannucchi and Goldman-Rakic, 1991). Clearly further work is required to unequivocally demonstrate whether cholinergic systems are substantially changed with age in the primate area 46.…”
Section: Neurotransmitter-specific Projections To Area 46 and Age-mentioning
This review is concerned with the effects of normal aging on the structure and function of prefrontal area 46 in the rhesus monkey (Macaca mulatta). Area 46 has complex connections with somatosensory, visual, visuomotor, motor and limbic systems and a key role in cognition, which frequently declines with age. An important question is what alterations might account for this decline. We are nowhere near having a complete answer, but as will be shown in this review, it is now evident that there is no single underlying cause. There is no significant loss of cortical neurons and although there are a few senile plaques in rhesus monkey cortex, their frequency does not correlate with cognitive decline. However, as discussed in this review, the following do correlate with cognitive decline. Loss of white matter, that has been proposed to result in some disconnections between parts of the central nervous system, and changes in the structure of myelin sheaths, that reduce conduction velocity and the timing in neuronal circuits. In addition, there are reductions in the inputs to cortical neurons, as shown by regression of dendritic trees, loss of dendritic spines and synapses, and alterations in transmitters and receptors. These factors contribute to alterations in the intrinsic and network physiological properties of cortical neurons. As more details emerge it is to be hoped that effective interventions to retard cognitive decline can be proposed.
“…Key words: antioxidants; aging; diet; dopamine; GABA; norepinephrine; striatum; cerebellum; cognitive behavior It is well known that there are numerous declines in central neuronal f unctioning that can occur in aging in the absence of neurodegenerative disease. These alterations may be manifested as a loss of neurotransmitter receptor sensitivity such as: (1) muscarinic (Amenta et al, 1989;Araujo et al, 1990;Joseph et al, 1990;Sherman and Friedman, 1990;Vannucchi, 1991;Viana et al, 1992;Yuf u et al, 1994;Egashira et al, 1996), (2) adrenergic (Burnett et al, 1990;Gelbmann and Muller, 1990;Gould and Bickford, 1997), (3) dopaminergic (Joseph et al, 1978;Roth and Joseph, 1994;Gould et al, 1996;Volkow et al, 1996;Araki et al, 1997;Z hang et al, 1997;Levine and C epeda, 1998), and (4) opioid (Dondi et al, 1992;Kornhuber et al, 1996;Nagahara et al, 1996).…”
Recent research has indicated that increased vulnerability to oxidative stress may be the major factor involved in CNS functional declines in aging and age-related neurodegenerative diseases, and that antioxidants, e.g., vitamin E, may ameliorate or prevent these declines. Present studies examined whether long-term feeding of Fischer 344 rats, beginning when the rats were 6 months of age and continuing for 8 months, with diets supplemented with a fruit or vegetable extract identified as being high in antioxidant activity, could prevent the age-related induction of receptor-mediated signal transduction deficits that might have a behavioral component. Thus, the following parameters were examined: (1) oxotremorine-enhanced striatal dopamine release (OX-K+-ERDA), (2) cerebellar beta receptor augmentation of GABA responding, (3) striatal synaptosomal 45Ca2+ clearance, (4) carbachol-stimulated GTPase activity, and (5) Morris water maze performance. The rats were given control diets or those supplemented with strawberry extracts (SE), 9.5 gm/kg dried aqueous extract (DAE), spinach (SPN 6.4 gm/kg DAE), or vitamin E (500 IU/kg). Results indicated that SPN-fed rats demonstrated the greatest retardation of age-effects on all parameters except GTPase activity, on which SE had the greatest effect, whereas SE and vitamin E showed significant but equal protection against these age-induced deficits on the other parameters. For example, OX-K+-ERDA enhancement was four times greater in the SPN group than in controls. Thus, phytochemicals present in antioxidant-rich foods such as spinach may be beneficial in retarding functional age-related CNS and cognitive behavioral deficits and, perhaps, may have some benefit in neurodegenerative disease.
“…The potential discrepancy in these studies is the age range used in each study. Previous studies used animals that were only 20 years old (Wagster et al 1990) or did not include middle-aged animals (Vannucchi and Goldman-Rakic 1991). In contrast, in the current study, we used adult, middle-aged, and aged animals, and our aged animals were 22-30 years.…”
Of the acetylcholine muscarinic receptors, the type 1 (M1) and type 2 (M2) receptors are expressed at the highest levels in the prefrontal cortex (PFC) and hippocampus, brain regions important for cognition. As equivocal findings of age-related changes of M1 and M2 in the nonhuman primate brain have been reported, we first assessed age-related changes in M1 and M2 in the PFC and hippocampus using saturation binding assays. Maximum M1 receptor binding, but not affinity of M1 receptor binding, decreased with age. In contrast, the affinity of M2 receptor binding, but not maximum M2 receptor binding, increased with age. To determine if in the elderly cognitive performance is associated with M1 or M2 function, we assessed muscarinic function in elderly female rhesus macaques in vivo using a scopolamine challenge pharmacological magnetic resonance imaging and in vitro using saturation binding assays. Based on their performance in a spatial maze, the animals were classified as good spatial performers (GSP) or poor spatial performers (PSP). In the hippocampus, but not PFC, the GSP group showed a greater change in T(2)*-weighted signal intensity after scopolamine challenge than the PSP group. The maximum M1 receptor binding and receptor binding affinity was greater in the GSP than the PSP group, but no group difference was found in M2 receptor binding. Parameters of circadian activity positively correlated with the difference in T(2)*-weighted signal intensity before and after the challenge, the maximum M1 receptor binding, and the M1 receptor binding affinity. Thus, while in rhesus macaques, there are age-related decreases in M1 and M2 receptor binding, in aged females, hippocampal M1, but not M2, receptor function is associated with spatial learning and memory and circadian activity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.